

510(k) Notification: MEDISISS Reprocessed ENT Ablation Wands (Coblators)

| Section 5: 510(K) Sum | nmary of Safety & Effectiveness | | | |
|-------------------------|--|--|--|--|
| Submitted By | MEDISISS 2747 SW 6 th St. Redmond, OR 97756 | | | |
| Contact Names | Redmond, OR 97756 Brandi James Sr. Director Quality Assurance/Regulatory Affairs P: 541-923-3310 F: 541-923-3375 E: bjames@MEDISISS.com | | | |
| Date Prepared | February 22, 2010 | | | |
| Proprietary Device Name | MEDISISS Reprocessed ENT Ablation Wands (Coblators) | | | |
| Classification | Electrosurgical Electrodes, Class II, Electrosurgical cutting and coagulation device and accessories, General and plastic surgery (21 CFR 878.4400), GEI | | | |
| Predicate Devices | K070374 ArthroCare ENT® Plasma Wands [™] K014290 ArthroCare ENTec® Plasma Wands [™] K063538 ArthroCare ENT® Plasma Wands [™] K013463 ArthroCare ArthroWands®, ENTec® EVac [™] Plasma Wand [™] K012669 MEDISISS Reprocessed Soft Tissue Ablators | | | |
| Intended Use | MEDISISS Reprocessed ENT Ablation Wands (Coblators) are indicated for coagulation, ablation, resection, of soft tissue and hemostasis of blood vessels in otoloaryngology (ENT) procedures including: tonsillectomy/adenoidectomy and soft tissue reduction. | | | |
| Device Description | The device is a high frequency, bipolar ablation wand with suction capability that contains an integrated electrical cable and integrated saline delivery system. | | | |
| Substantial Equivalence | The indications for use, technological characteristics, and performance specifications are substantially equivalent to the predicate devices. | | | |

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

MEDISISS

% Ms. Brandi J. James Sr. Director, Quality Assurance/ Regulatory Affairs 2747 SW 6th Street Redmond, Oregon 97756

JUL 2 3 2010

Re: K100543

Trade/Device Name: Medisiss Reprocessed ENT Ablation Wands

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device

and accessories

Regulatory Class: Class II

Product Code: GEI

Dated: February 22, 2010 Received: February 25, 2010

Dear Ms. James:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic

And Restorative Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure



510(k) Notification:
MEDISISS Reprocessed
ENT Ablation Wands (Coblators)
All Information on This Page is Confidential

| • | | | |
|---|----------------------------|--|-----------------------|
| Section 4: Indications fo | or Use | | |
| | • | | |
| 510(k) Number: TBD | | | |
| <u>Device Name:</u> MEDISISS Reproc | essed ENT Ablation Wand | ls (Coblators) | |
| Indications For Use: | | | |
| MEDISISS Reprocessed ENT Abl tissue and hemostasis of blood ves tonsillectomy/adenoidectomy and | sels in otoloaryngology (E | re indicated for coagulation, ablation NT) procedures including: | ı, resection, of soft |
| | | | |
| | | | |
| | | · | |
| | , | | |
| | | | |
| • | | • | |
| Prescription Use X (Part 21 CFR 801.109) | AND/OR | Over-The-Counter Use(21 CFR 807 Subpart C) | |
| (PLEASE DO NOT WRITE BI | ELOW THIS LINE-CONT | INUE ON ANOTHER PAGE IF N | EEDED) |
| Concurrer | ice of CDRH, Office of De | evice Evaluation (ODE) | |
| Mark M. | Milhers_ | | |
| (Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices | | Page 1 of | |
| 510(k) Number | <100543 | | |